atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
Posted:
Atai Life Sciences a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day. Read more here.
Memora helps health systems and payers to incorporate AI-driven workflow-automation technology.
The platform sends patient-reported concerns and data to clinical care team members and offers two-way communication and support, the company said.
Read the full article in the latest Healthcare Finance…
Information included payment details such as credit card or bank account numbers and insurance info ranging from Medicaid and Medicare IDs to policy numbers and claims. Secure EHR data was not accessed.
Read the full article in the latest Healthcare IT…
Attendees
Sponsors and
Exhibitors
Webinars
Contact us